Emerging drugs for hepatitis B. (Q35359369)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

review article

1 reference

title

Emerging drugs for hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Fabien Zoulim

1 reference

PubMed publication ID

17604497

7 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

199-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

New and emerging treatment of chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

The level of viral antigen presented by hepatocytes influences CD8 T-cell function.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Antiviral therapy of chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

In vitro models for studying hepatitis B virus drug resistance

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Entecavir: a new treatment option for chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Clinical trial results of new therapies for HBV: implications for treatment guidelines

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Management of HBV Infection in Liver Transplantation Patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Lamivudine for patients with chronic hepatitis B and advanced liver disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Hepatitis B virus infection--natural history and clinical consequences

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Hepatocyte turnover during resolution of a transient hepadnaviral infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Translation of immunological knowledge into better treatments of chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Coadministration of gamma interferon with DNA vaccine expressing woodchuck hepatitis virus (WHV) core antigen enhances the specific immune response and protects against WHV infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Hepatitis B virus biology

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Interleukin-12 inhibits hepatitis B virus replication in transgenic mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Long-lasting memory T cell responses following self-limited acute hepatitis B

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

12 July 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Liver transplantation in patients with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Pharmacokinetics of pradefovir and PMEA in healthy volunteers after oral dosing of pradefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Lamivudine therapy of WHV-infected woodchucks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-gamma-secreting T cells after DNA-based immunization

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3194402

Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection

26 September 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.12.2.199

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

21 January 2018

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

1 reference

12 December 2020

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

12 December 2020

10.1517/14728214.12.2.199

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

PubMed publication ID

17604497

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17604497%20AND%20SRC:MED&resulttype=core&format=json